Medicine and Dentistry
Acute Heart Infarction
25%
Analysis
28%
Antibody
28%
Association
30%
Breast Cancer
25%
Cancer of Unknown Primary Origin
25%
Cell Aggregation
25%
Cell Expansion
20%
Cells
54%
Chronic Hepatitis C
25%
Cohort Analysis
25%
Combination Therapy
43%
CpG Oligodeoxynucleotide
20%
Differentiation
32%
Esophageal Cancer
25%
Ex Vivo
17%
Experience
28%
Growth
25%
Hazard Ratio
20%
Hepatocellular Carcinoma
25%
Human Leukocyte Antigen
25%
Immune Checkpoint Inhibitor
33%
Inducible Nitric Oxide Synthase
25%
Inpatient
53%
Liver
25%
Liver Failure
25%
Liver Tumor
20%
Lymph Node
25%
Maturation
25%
Metastatic Colorectal Cancer
25%
Monitoring
20%
Myeloid Cell
25%
Myeloid-Derived Suppressor Cell
25%
Neoplasm
48%
Nodular Melanoma
51%
Overall Survival
37%
Paracetamol
25%
Patient
100%
Primary Tumor
25%
Prognostic Factor
26%
Progression Free Survival
19%
Standardized Uptake Value
25%
Survival
57%
T Cell
52%
T-Helper Cell
25%
Therapeutic Procedure
43%
Treatment Response
25%
Tumor Microenvironment
30%
Tumor Model
20%
Tumor Progression
21%
Immunology and Microbiology
Antineoplastic Activity
25%
Aptitude
18%
Association
25%
CD4
25%
Cell Aggregation
25%
Cell Expansion
17%
Cells
45%
Cluster of Differentiation
25%
CpG Oligodeoxynucleotide
17%
Cytokine
17%
Cytotoxic T-Cell
53%
Growth
29%
Hepatitis C
25%
Human Leukocyte Antigen
25%
Immunity
27%
Liver
58%
Maturation
25%
Molecule
28%
Monospecific Antibody
28%
Mouse
12%
Myeloid
25%
Myeloid-Derived Suppressor Cell
25%
Neutrophil Granulocyte
7%
Overall Survival
9%
Phenotype
10%
Progression Free Survival
9%
Survival
25%
T Cell
23%
T Cell Receptor
7%
TLR9
8%
Tumor Necrosis Factor Alpha
5%
Viral Hepatitis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Infarction
25%
Adverse Event
7%
Antiemetic Agent
25%
Aprepitant
25%
Cancer Risk
25%
Carcinoembryonic Antigen
5%
Chemotherapy
25%
Cisplatin
25%
Colon Cancer
25%
Combination Drug
6%
Dexamethasone
25%
Diseases
14%
Epidermolysis
25%
HLA B51 Antigen
11%
Liver Metastasis
6%
Malignant Neoplasm
11%
Melanoma
25%
Metastatic Colorectal Cancer
25%
Neoplasm
13%
Nivolumab
6%
Overall Survival
14%
Palonosetron
25%
Pembrolizumab
6%
Progression Free Survival
9%
Recurrent Disease
5%
RNA-Sequencing
5%